

# Second Annual Olfactory Neuroblastoma (Esthesioneuroblastoma) Patient Education Meeting

**When:** Saturday, February 27, 2021, 10 a.m. to 1 p.m.  
Eastern time

**Where:** Virtual meeting.

**WebEx meeting link:** <https://nih.webex.com/nih/j.php?MTID=m3fab80d3bbd5da377c0d29798717411e>  
Meeting number: 126 923 4105

**Password:** SPjPxcUK224  
Call-in number (US/Canada): 1-650-479-3208

Meeting password and call-in number are the same for every link.

## Breakout session #1

**WebEx meeting link:** <https://nih.webex.com/nih/j.php?MTID=m97fba9531974ae9006058fcdf438da4c>  
Meeting number: 126 086 3529

## Breakout session #2

**WebEx meeting link:** <https://nih.webex.com/nih/j.php?MTID=m2d859a8bd0385cc3cb12e2c07c0e2066>  
Meeting number: 126 927 2020

## Breakout session #3

**WebEx meeting link:** <https://nih.webex.com/nih/j.php?MTID=ma308c587f6db110ccc94de6def9a7edb>  
Meeting number: 126 799 7332

## Breakout session #4

**WebEx meeting link:** <https://nih.webex.com/nih/j.php?MTID=m0fe9035331290db88d1e454c216e15b0>  
Meeting number: 126 009 1335



## Rare Disease Day 2021

Sunday, February 28, 2021, is Rare Disease Day worldwide. NIH will hold **Rare Disease Day** events on Monday, March 1, 2021, virtually.

<https://ncats.nih.gov/news/events/rdd>



*Participants in the first annual meeting, held in February 2020.*

**Who:** Presenters will include people personally affected by olfactory neuroblastoma, and medical and scientific experts from the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Cancer Institute (NCI), Johns Hopkins, and other major hospital centers throughout the United States.

**What:**

- Perspectives from patients and family members affected by olfactory neuroblastoma.
- Information on advances in surgery, radiation, and other treatments.
- Research updates on genomics, outcomes, and clinical studies.
- Information about clinical trials.

This meeting is directed by Nyall R. London, Jr., M.D., Ph.D.; Gary Gallia, M.D., Ph.D.; and Murray Ramanathan, M.D.; and is sponsored by the NIDCD.

Please direct any questions or reasonable accommodation requests to Dr. London, principal investigator of the NIDCD Sinonasal and Skull Base Tumor Program (<https://www.nidcd.nih.gov/research/labs/sinonasal-and-skull-base-tumor-program>), at [nyall.london@nih.gov](mailto:nyall.london@nih.gov) or 301-402-4216.



National Institute on  
Deafness and Other  
Communication Disorders